SplitNov 9, 2026, 07:31 AM
Silexion Therapeutics Announces 1-for-24 Reverse Share Split
AI Summary
Silexion Therapeutics Corp. announced a 1-for-24 reverse share split of its ordinary shares, effective after market close on November 10, 2026. Trading on a split-adjusted basis will commence on November 11, 2026, under the existing ticker symbol SLXN. This move is intended to help the company regain compliance with Nasdaq's minimum bid price requirement, enhance its market position, and support its clinical progress with SIL204. No fractional shares will be issued, with entitlements rounded up to the nearest whole share.
Key Highlights
- Silexion Therapeutics announces a 1-for-24 reverse share split.
- The reverse split will become effective after market close on November 10, 2026.
- Trading on a split-adjusted basis will begin at market open on November 11, 2026.
- The reverse split aims to regain compliance with Nasdaq minimum bid price requirement.
- No fractional shares will be issued; fractional entitlements will be rounded up.
- Par value per share will increase from $0.135 to $3.24.
Price Impact
More from SLXN